Skip to content

Novavax NVAX Support Services — Total Revenue

Other product segments

Royalties
$3.52M

Similar metrics at other companies

Open Text logo
OTEXCustomer support — Total revenues
$564.85M-0.4%
UCT
UCTTServices — Total revenues
$68M+10.4%
TETRA Technologies logo
TTIServices — Total Revenue
$72.96M+5.8%
Pitney Bowes logo
PBIServices — Total Revenue
$306.57M-3.7%
Azenta logo
AZTAServices — Total Revenue
$107.15M+5.6%
A10 Networks logo
ATENServices — Total net revenue
$31.01M+2.8%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's support services — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's support services — total revenue?
Novavax (NVAX) reported support services — total revenue of $100K in Q1 2026.
What does support services — total revenue mean?
This metric represents the total gross revenue generated from specialized support services provided to third-party partners or collaborators. It reflects the financial contribution of service-based activities, such as technical assistance, manufacturing support, or collaborative research efforts, distinct from direct product sales. Monitoring this revenue stream helps investors assess the company's ability to monetize its technical expertise and infrastructure beyond its core vaccine product portfolio.